Press

Revitalist and Wake Network Enter Joint Venture Offering National and International Access to Psychedelics for Veterans

Sep 13 • 3 min read

Revitalist Lifestyle and Wellness LTD (CSE: CALM | OTCQB: RVLWF | FSE: 4DO), Revitalist and Wake Network, Inc. will now be jointly offering ketamine infusions in the United States and psilocybin clinical retreats internationally with a special focus on Veteran’s ethical need for access, establishing the world’s first international center of excellence. Psilocybin and Ketamine…

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Sep 12 • 6 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received approval to conduct a Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-dimethyl tryptamine” or “DMT”) for the treatment of stroke in the Netherlands from the Stichting Beoordeling Ethiek…

Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home

Sep 12 • 3 min read

Braxia Scientific Corp (CSE: BRAX | OTC: BRAXF | FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce it has successfully launched KetaMD in Florida. KetaMD onboarded new patients and completed initial ketamine treatments. Eligible patients, as determined by…

Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program

Sep 12 • 4 min read

Awakn Life Sciences Corp. (NEO: AWKN | OTCQB: AWKNF | FSE: 954), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder, today announces it has signed a drug development agreement with Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners…

Lobe Sciences Announces Closing of Private Placement

Sep 8 • 3 min read

Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease, today announced that it has closed a non-brokered private placement of units for gross proceeds of $1,347,500. “We are extremely pleased to close this financing and are thankful for the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441